Literature DB >> 21569208

Protein aggregation and amyloid fibril formation prediction software from primary sequence: towards controlling the formation of bacterial inclusion bodies.

Stavros J Hamodrakas1.   

Abstract

Proteins might aggregate into ordered or amorphous structures, utilizing relatively short sequence stretches, usually organized in β-sheet-like assemblies. Here, we attempt to list all available software, developed during the last decade or so, for the prediction of such aggregation-prone stretches from protein primary structure, without distinguishing whether these algorithms predict amino acid sequences destined to be involved in ordered fibrillar amyloids or amorphous aggregates. The results of application of four of these programs on 23 proteins related to amyloidoses are compared. Because protein aggregation during protein production in bacterial cell factories has been shown to resemble amyloid formation, the algorithms might become useful tools to improve the solubility of recombinant proteins and for screening therapeutic approaches against amyloidoses under conditions that mimic physiologically relevant environments. One such example is given.
© 2011 The Author Journal compilation © 2011 FEBS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21569208     DOI: 10.1111/j.1742-4658.2011.08164.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  18 in total

Review 1.  The diversity and utility of amyloid fibrils formed by short amyloidogenic peptides.

Authors:  Zahraa S Al-Garawi; Kyle L Morris; Karen E Marshall; Jutta Eichler; Louise C Serpell
Journal:  Interface Focus       Date:  2017-10-20       Impact factor: 3.906

2.  ANTISOMA: A Computational Pipeline for the Reduction of the Aggregation Propensity of Monoclonal Antibodies.

Authors:  Katerina C Nastou; Eleftheria G Karataraki; Nikos C Papandreou; Anna-Isavella G Rerra; Vassiliki P Grimanelli; Ilias Maglogiannis; Stavros J Hamodrakas; Vassiliki A Iconomidou
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

3.  Amyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing - a common mechanism of apolipoprotein A-I misfolding in familial amyloidosis and atherosclerosis.

Authors:  Madhurima Das; Xiaohu Mei; Shobini Jayaraman; David Atkinson; Olga Gursky
Journal:  FEBS J       Date:  2014-04-28       Impact factor: 5.542

4.  Zinc enhances carnosine inhibitory effect against structural and functional age-related protein alterations in an albumin glycoxidation model.

Authors:  Hichem Moulahoum; Faezeh Ghorbanizamani; Suna Timur; Figen Zihnioglu
Journal:  Biometals       Date:  2020-09-30       Impact factor: 2.949

5.  Origins of amyloid-β.

Authors:  William G Tharp; Indra Neil Sarkar
Journal:  BMC Genomics       Date:  2013-04-30       Impact factor: 3.969

6.  Motif mining: an assessment and perspective for amyloid fibril prediction tool.

Authors:  Smitha Sunil Kumaran Nair; Nv Subba Reddy; Ks Hareesha
Journal:  Bioinformation       Date:  2012-01-20

7.  Structural mechanism for modulation of functional amyloid and biofilm formation by Staphylococcal Bap protein switch.

Authors:  Junfeng Ma; Xiang Cheng; Zhonghe Xu; Yikan Zhang; Jaione Valle; Shilong Fan; Xiaobing Zuo; Iñigo Lasa; Xianyang Fang
Journal:  EMBO J       Date:  2021-05-28       Impact factor: 14.012

8.  A consensus method for the prediction of 'aggregation-prone' peptides in globular proteins.

Authors:  Antonios C Tsolis; Nikos C Papandreou; Vassiliki A Iconomidou; Stavros J Hamodrakas
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

9.  Protein aggregation profile of the human kinome.

Authors:  Ricardo Graña-Montes; Ricardo Sant'anna de Oliveira; Salvador Ventura
Journal:  Front Physiol       Date:  2012-11-20       Impact factor: 4.566

10.  Prediction of Peptide and Protein Propensity for Amyloid Formation.

Authors:  Carlos Família; Sarah R Dennison; Alexandre Quintas; David A Phoenix
Journal:  PLoS One       Date:  2015-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.